BioCentury | Sep 15, 2020
Finance

Sept. 14 Quick Takes: $70M+ rounds for Escient, Escape, plus Alzheimer’s data lifts Cassava shares and more

...multiple disease pathways in  a Phase IIb study funded by NIH. Orasis raises $30M for ophthalmic pipeline  Orasis Pharmaceuticals Ltd....
BioCentury | Oct 26, 2018
Company News

Management tracks: Principia, Orexo, Polyphor, MeiraGTx

...Aug. 31. Unninayar was CFO at antibiotic resistance company Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH). Ophthalmology company Orasis Pharmaceuticals Ltd....
...senior associate at SV Health Investors LLP (Boston, Mass.) BC Staff Apitope International N.V. Harvard Bioscience Inc. Tetraphase Pharmaceuticals Inc. Orasis Pharmaceuticals Ltd....
Items per page:
1 - 2 of 2
BioCentury | Sep 15, 2020
Finance

Sept. 14 Quick Takes: $70M+ rounds for Escient, Escape, plus Alzheimer’s data lifts Cassava shares and more

...multiple disease pathways in  a Phase IIb study funded by NIH. Orasis raises $30M for ophthalmic pipeline  Orasis Pharmaceuticals Ltd....
BioCentury | Oct 26, 2018
Company News

Management tracks: Principia, Orexo, Polyphor, MeiraGTx

...Aug. 31. Unninayar was CFO at antibiotic resistance company Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH). Ophthalmology company Orasis Pharmaceuticals Ltd....
...senior associate at SV Health Investors LLP (Boston, Mass.) BC Staff Apitope International N.V. Harvard Bioscience Inc. Tetraphase Pharmaceuticals Inc. Orasis Pharmaceuticals Ltd....
Items per page:
1 - 2 of 2